AST Business Growth & Strategic Acquisitions Support STERIS Stock
STE frequently engages in strategic acquisitions and joint ventures to optimize its portfolio of businesses.
Is it the Right Time to Hold STERIS Stock in Your Portfolio?
STE stays on investors' radars due to the strength of its Healthcare arm and strong rebound potential in the AST segment.
Deciphering Steris (STE) International Revenue Trends
Examine Steris' (STE) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Steris: May Benefit From Bringing Pharmaceutical Manufacturing Back To The U.S.
Steris plc remains a Strong Buy with a fair value of $281, supported by robust organic growth and margin expansion. The Trump administration's push to reshore pharma manufacturing could be a major tailwind for Steris's AST business. Steris's balanced growth in pricing and volume, along with cost initiatives, positions it for continued operating margin improvement.
STERIS plc (STE) Q4 2025 Earnings Call Transcript
STERIS plc (NYSE:STE ) Q4 2025 Results Conference Call May 15, 2025 9:00 AM ET Company Participants Julie Winter - Investor Relations Mike Tokich - Senior Vice President and Chief Financial Officer Dan Carestio - President and Chief Executive Officer Conference Call Participants Dave Turkaly - Citizens Mike Matson - Needham & Company Patrick Wood - Morgan Stanley Mac Etoch - Stephens, Inc Michael Polark - Wolfe Research Jason Bednar - Piper Sandler Brett Fishbin - KeyBanc Operator Good morning, everyone, and welcome to the STERIS plc Fourth Quarter 2025 Conference Call. All participants will be in a listen-only mode.
STE Q4 Earnings Beat, Margins Expand, Stock Up in Aftermarket
STERIS' fourth-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues.
Here's What Key Metrics Tell Us About Steris (STE) Q4 Earnings
Although the revenue and EPS for Steris (STE) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Steris (STE) Surpasses Q4 Earnings Estimates
Steris (STE) came out with quarterly earnings of $2.74 per share, beating the Zacks Consensus Estimate of $2.59 per share. This compares to earnings of $2.41 per share a year ago.
Steris forecasts annual profit above estimates on strong medical equipment sales
Medical equipment maker Steris forecast annual profit above analysts' estimate on Wednesday, banking on strength in its biggest segment that sells sterilization products, sending its shares up more than 5% in extended trading.
Steris Fiscal Fourth-Quarter 2025 Financial Results: Just the Numbers
Medical equipment maker Steris (STE) on Wednesday afternoon reported fiscal fourth-quarter 2025 financial results. A summary of its key numbers is below.
What Analyst Projections for Key Metrics Reveal About Steris (STE) Q4 Earnings
Get a deeper insight into the potential performance of Steris (STE) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Will Applied Sterilization Growth Help STE Beat Q4 Earnings Estimates?
STERIS is expected to have experienced an increase in bioprocessing demand in the fourth quarter.
